Phase 3 Clinical Trial
MagnetisMM-32 Study

Advancing Treatment Options for Relapsed Multiple Myeloma

Join a clinical research study evaluating an investigational medicine, elranatamab, for adults whose multiple myeloma has returned after prior treatments. Discover hope through next-generation therapy research.

See If You Qualify Learn More
Seeking adults 18+
Expert medical monitoring
Evaluating new therapies

Hope Through Research

Exploring innovative approaches for patients with relapsed multiple myeloma.

Active Phase 3 Study

Dedicated Care

Continuous follow-up by study clinic professionals.

About the MagnetisMM-32 Study

Advancing Treatment Options for Relapsed Multiple Myeloma

Study Purpose

The purpose of this study is to evaluate an investigational medicine called elranatamab. This clinical trial aims to compare elranatamab to established combination therapies for the treatment of Multiple Myeloma (MM) that has returned or stopped responding to previous treatments, including prior anti-CD38 antibody and lenalidomide therapies.

What to Expect

  • Randomized Assignment Participants will be assigned to receive either elranatamab or a combination therapy selected by the study doctor.
  • Administration Elranatamab is given as an injection under the skin at the clinic, initially about once a week.
  • Ongoing Monitoring The study team will closely monitor your health and response to the treatment during regular clinic visits.

Phase 3

Clinical Trial

Multiple Myeloma

Target Condition

Ongoing

Treatment Duration

Pfizer

Study Sponsor

Study Phase 3

Who Can Participate?

We are looking for individuals with relapsed Multiple Myeloma to help us explore innovative therapy options. Review the general guidelines below to see if this study might be a fit for you.

You May Qualify If...

  • Age & Diagnosis: You are 18 years of age or older and have been diagnosed with Multiple Myeloma.
  • Prior Treatments: You have received 1 to 4 previous treatments, which must include an anti-CD38 antibody and lenalidomide.
  • Disease Status: Your myeloma has returned or did not respond to your most recent treatment.
  • Overall Health: You have acceptable results from standard lab tests and are generally able to carry out daily activities.

You May Not Qualify If...

  • Related Conditions: You have a condition like smoldering myeloma, plasma cell leukemia, or amyloidosis.
  • Disease Spread: Your myeloma has spread to your central nervous system (brain or spinal cord).
  • Recent Procedures: You had a stem cell transplant within the last 12 weeks.
  • Other Health Issues: You have an active, uncontrolled infection or another active cancer (with minor skin exceptions).
  • Specific Therapies: You have previously received BCMA-directed or CD3-redirecting therapies.

Not sure if you qualify?

These are only partial guidelines. Take our quick eligibility quiz to help determine if this research study is an option for you.

Find a Location Near You

Study Benefits & Care

By participating in the MagnetisMM-32 study, you will receive comprehensive medical attention while helping to advance new possibilities for relapsed multiple myeloma.

Study Medication

Receive the investigational medicine, Elranatamab, or a selected standard combination therapy provided at no cost to you during the study.

Expert Medical Care

Gain access to a dedicated healthcare team and receive regular health evaluations, laboratory tests, and close monitoring of your multiple myeloma.

Advancing Research

Play a vital role in clinical research, contributing to the scientific understanding and evaluation of next-generation therapies for patients worldwide.